Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom
information for practice,
Midostaurin (MIDO) has been proposed for the treatment of newly-diagnosed adult patients with FMS-like tyrosine kinase 3…